Coeliac disease is usually managed as a digestive condition: remove gluten, heal the gut, discharge the patient. A matched cohort study led by Karolinska Institutet researchers Philip Curman and Jonas Ludvigsson, published in The Lancet Regional Health Americas, suggests that long-term follow-up should look wider. Using large United States registry data, the team examined outcomes in just over 200,000 adults with coeliac disease and nearly 7,000 with the related skin condition dermatitis herpetiformis.
People with coeliac disease had slightly higher rates of major cardiovascular events, including heart attack, stroke and heart failure, and an 18 per cent higher risk of death during follow-up compared with matched controls. They also carried an increased risk of blood cancers, particularly non-Hodgkin lymphoma, though reassuringly no elevated risk of solid tumours. For dermatitis herpetiformis, the cardiovascular and mortality signals were more uncertain across the analyses.
The findings argue that care for people with coeliac disease should extend beyond gluten-free dietary management to long-term clinical follow-up that keeps cardiovascular and haematological health in view. They also illustrate the scientific value of pairing Scandinavian registry epidemiology expertise with very large American datasets, an approach that allows associations far too subtle for single-centre studies to be detected and quantified with reasonable confidence.